EZH2，前列腺癌的表观遗传驱动因子。
EZH2, an epigenetic driver of prostate cancer.
机构信息
Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
出版信息
Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30.
Abstract
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
摘要
组蛋白甲基转移酶 EZH2 自首次发现其在转移性前列腺癌中表达升高以来，已经成为癌症表观遗传学领域的焦点十年。由于其在癌症发展过程中的重要作用及其作为有效治疗靶点的潜力，它仍然吸引着大量的科学关注。因此，我们在这里回顾了 EZH2 在前列腺癌中的失调、它的功能、上游调节剂、下游效应物以及 EZH2 靶向方法的现状。因此，本综述提供了 EZH2 在前列腺癌中的全面概述。
相似文献
1
EZH2, an epigenetic driver of prostate cancer.EZH2，前列腺癌的表观遗传驱动因子。
Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30.
2
Going beyond Polycomb: EZH2 functions in prostate cancer.超越 Polycomb：EZH2 在前列腺癌中的功能。
Oncogene. 2021 Sep;40(39):5788-5798. doi: 10.1038/s41388-021-01982-4. Epub 2021 Aug 4.
3
Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.肿瘤分泌的热休克蛋白90破坏多梳蛋白功能，从而驱动前列腺肿瘤的生长和侵袭。
J Biol Chem. 2015 Mar 27;290(13):8271-82. doi: 10.1074/jbc.M115.637496. Epub 2015 Feb 10.
4
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.BRCA1 和 EZH2 合作调节前列腺癌干细胞表型。
Int J Cancer. 2019 Dec 1;145(11):2974-2985. doi: 10.1002/ijc.32323. Epub 2019 May 10.
5
Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.前列腺癌细胞中组成型活性催乳素受体的表达导致p53基因的组蛋白三甲基化。
Chin J Physiol. 2013 Oct 31;56(5):282-90. doi: 10.4077/CJP.2013.BAB139. Epub 2013 Aug 31.
6
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.在去势抵抗性前列腺癌细胞中，EZH2 致癌活性是独立于 Polycomb 的。
Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.
7
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.SRA 蛋白 UHRF1 促进表观遗传串扰，并参与前列腺癌的进展。
Oncogene. 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13.
8
EZH2 in Bladder Cancer, a Promising Therapeutic Target.EZH2在膀胱癌中：一个有前景的治疗靶点
Int J Mol Sci. 2015 Nov 13;16(11):27107-32. doi: 10.3390/ijms161126000.
9
Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.实体瘤中的表观遗传重编程：EZH2功能获得性突变的治疗意义
Epigenomics. 2015 Aug;7(5):687-90. doi: 10.2217/epi.15.27. Epub 2015 Aug 28.
10
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.水飞蓟宾作为人类前列腺癌中一种假定的表观遗传调节剂的新作用。
Molecules. 2016 Dec 31;22(1):62. doi: 10.3390/molecules22010062.
引用本文的文献
1
G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications.G9a在癌症中的作用：机制、治疗进展及临床意义
Cancers (Basel). 2024 Jun 8;16(12):2175. doi: 10.3390/cancers16122175.
2
Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.雄激素剥夺通过CREB1/EZH2介导的REST下调诱导前列腺癌细胞中的神经内分泌表型。
Cell Death Discov. 2024 May 22;10(1):246. doi: 10.1038/s41420-024-02031-1.
3
Construction and validation of a chromatin regulator-related gene signature for prognostic and therapeutic significance of clear cell renal cell carcinoma.用于透明细胞肾细胞癌预后和治疗意义的染色质调节因子相关基因特征的构建与验证
Transl Cancer Res. 2024 Jan 31;13(1):150-172. doi: 10.21037/tcr-23-1383. Epub 2024 Jan 15.
4
Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.雄激素剥夺通过CREB1/EZH2介导的REST下调诱导前列腺癌细胞中的神经内分泌表型。
Res Sq. 2023 Oct 4:rs.3.rs-3270539. doi: 10.21203/rs.3.rs-3270539/v1.
5
Zinc Ions Modulate YY1 Activity: Relevance in Carcinogenesis.锌离子调节YY1活性：在致癌作用中的相关性。
Cancers (Basel). 2023 Aug 30;15(17):4338. doi: 10.3390/cancers15174338.
6
Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.下调 EZH2 抑制恩杂鲁胺耐药前列腺癌中的上皮间质转化。
Prostate. 2023 Nov;83(15):1458-1469. doi: 10.1002/pros.24602. Epub 2023 Jul 20.
7
H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.男性泌尿生殖系统癌症中的H3组蛋白甲基化格局：从分子机制到表观遗传生物标志物和治疗靶点。
Front Cell Dev Biol. 2023 May 9;11:1181764. doi: 10.3389/fcell.2023.1181764. eCollection 2023.
8
Bioinspired Lipid Nanocarriers for RNA Delivery.用于RNA递送的仿生脂质纳米载体
ACS Bio Med Chem Au. 2023 Jan 16;3(2):114-136. doi: 10.1021/acsbiomedchemau.2c00073. eCollection 2023 Apr 19.
9
The epigenetic function of androgen receptor in prostate cancer progression.雄激素受体在前列腺癌进展中的表观遗传功能
Front Cell Dev Biol. 2023 Mar 21;11:1083486. doi: 10.3389/fcell.2023.1083486. eCollection 2023.
10
Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2.多西他赛通过锌指同源物2增强子的表观遗传基因调控增强肿瘤坏死因子相关凋亡诱导配体介导的前列腺癌细胞凋亡。
World J Mens Health. 2023 Jul;41(3):649-658. doi: 10.5534/wjmh.220073. Epub 2023 Jan 1.
本文引用的文献
1
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.EZH2 抑制作为 EZH2 激活突变淋巴瘤的治疗策略。
Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.
2
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.用于EZH2肽和核小体高通量筛选的试剂及检测方法的开发与验证
J Biomol Screen. 2012 Dec;17(10):1279-92. doi: 10.1177/1087057112453765. Epub 2012 Aug 17.
3
Current and emerging treatments in the management of castration-resistant prostate cancer.目前和新兴的治疗方法在去势抵抗性前列腺癌的管理。
Expert Rev Anticancer Ther. 2012 Jul;12(7):951-64. doi: 10.1586/era.12.59.
4
ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.维甲酸通过降低 HOXB13 基因的甲基化水平抑制 DU145 前列腺癌细胞的增殖。
PLoS One. 2012;7(7):e40943. doi: 10.1371/journal.pone.0040943. Epub 2012 Jul 13.
5
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.多梳蛋白 EZH2 通过转录抑制乳腺癌和前列腺癌中的转移抑制因子 RKIP 来调节肿瘤侵袭。
Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.
6
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.前列腺癌中 let-7 的缺失可上调 EZH2，同时获得癌症干细胞特征，BR-DIM 可减弱这些特征。
PLoS One. 2012;7(3):e33729. doi: 10.1371/journal.pone.0033729. Epub 2012 Mar 19.
7
The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.EZH2 在调节前列腺癌细胞基质金属蛋白酶活性中的作用。
PLoS One. 2012;7(1):e30393. doi: 10.1371/journal.pone.0030393. Epub 2012 Jan 17.
8
Cooperation between Polycomb and androgen receptor during oncogenic transformation.多梳抑制复合物和雄激素受体在致癌转化过程中的合作。
Genome Res. 2012 Feb;22(2):322-31. doi: 10.1101/gr.131508.111. Epub 2011 Dec 16.
9
Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.通过形成瞬态苯硼酸-药物复合物将 3-去氮氮胞苷载入聚乙二醇化的单层脂质体及其在 Sprague-Dawley 大鼠中的药代动力学特征。
Eur J Pharm Biopharm. 2012 Feb;80(2):323-31. doi: 10.1016/j.ejpb.2011.10.014. Epub 2011 Oct 28.
10
16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells.16-羟基克氏千里光二萜-15,16-内酯通过调节组蛋白修饰酶 PRC2 复合物的表达诱导 CML K562 细胞凋亡。
Life Sci. 2011 Dec 5;89(23-24):886-95. doi: 10.1016/j.lfs.2011.09.011. Epub 2011 Sep 29.
Zotero 插件